Emergent BioSolutions | EBS - Loan Capital


Emergent BioSolutions reported $446.5M in Loan Capital for its fiscal quarter ending in December of 2023.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Akebia Therapeutics USD 48.25M 609K Dec/2025
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
ANI Pharmaceuticals USD 291.84M 5.84M Dec/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Coherus Biosciences USD 51.08M 496K Dec/2025
Emergent BioSolutions USD 446.5M 1.7M Dec/2023
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Lexicon Pharmaceuticals USD 49.41M 7.1M Dec/2025
Lonza CHF 3.88B 323M Dec/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Myriad Genetics USD 119.9M 400K Dec/2025
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pacira USD 372.19M 4.53M Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Xoma USD 94.38M 7.82M Sep/2025